Feb 6 (Reuters) - Aduro Biotech Inc:
* ADURO BIOTECH ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF PHASE 2 TRIAL OF ANTI-CD27 AGONIST MK-5890 IN NON-SMALL CELL LUNG CANCER
* ADURO BIOTECH- EARNED $10 MILLION DEVELOPMENT MILESTONE PAYMENT UNDER WORLDWIDE LICENSING DEAL WITH MERCK FOR PHASE 2 CLINICAL TRIAL OF MK-5890 INITIATION Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.